|
ZBTB4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.56159996045346E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.68750000218677E-08 |
| Normal-vs-Stage2 |
1.303860E-03 |
| Normal-vs-Stage3 |
8.82899975351847E-10 |
| Normal-vs-Stage4 |
6.86290000051493E-07 |
| Stage1-vs-Stage2 |
3.988000E-01 |
| Stage1-vs-Stage3 |
6.628100E-02 |
| Stage1-vs-Stage4 |
2.245000E-01 |
| Stage2-vs-Stage3 |
3.750100E-02 |
| Stage2-vs-Stage4 |
1.072250E-01 |
| Stage3-vs-Stage4 |
8.831200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.33099983759644E-10 |
| Normal-vs-AfricanAmerican |
2.182000E-01 |
| Normal-vs-Asian |
3.648100E-04 |
| Caucasian-vs-AfricanAmerican |
3.083700E-03 |
| Caucasian-vs-Asian |
2.571800E-01 |
| AfricanAmerican-vs-Asian |
9.410000E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.97490000411571E-08 |
| Normal-vs-Female |
9.70299995906032E-09 |
| Male-vs-Female |
7.733400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.93190000008903E-07 |
| Normal-vs-Age(41-60Yrs) |
3.11840000488672E-08 |
| Normal-vs-Age(61-80Yrs) |
9.30710000179857E-08 |
| Normal-vs-Age(81-100Yrs) |
2.761400E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.158400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.861000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.492400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.755600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.168400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.616000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.59059000000017E-05 |
| Classical-VS-Follicular |
7.219800E-01 |
| Classical-VS-Other |
4.909000E-01 |
| Classical-VS-Normal |
1.91249999947907E-07 |
| Tall-VS-Follicular |
4.762000E-04 |
| Tall-VS-Other |
1.751610E-01 |
| Tall-VS-Normal |
5.22990539764123E-11 |
| Follicular-VS-Other |
6.023000E-01 |
| Follicular-VS-Normal |
2.06520000000099E-05 |
| Other-VS-Normal |
1.531940E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.03330000000845E-07 |
| Normal-vs-N1 |
2.66959999994931E-07 |
| N0-vs-N1 |
2.075400E-01 |
|
|
